Otonomy Stock Forecast, Price & News

Otonomy (NASDAQ:OTIC) Frequently Asked Questions

Is Otonomy a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Otonomy stock.
View analyst ratings for Otonomy or view top-rated stocks.

How has Otonomy's stock been impacted by Coronavirus (COVID-19)?

Otonomy's stock was trading at $2.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OTIC stock has decreased by 13.4% and is now trading at $2.27.
View which stocks have been most impacted by COVID-19.

When is Otonomy's next earnings date?

Otonomy is scheduled to release its next quarterly earnings announcement on Thursday, February 10th 2022.
View our earnings forecast for Otonomy.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) issued its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.19). Otonomy had a negative net margin of 20,278.95% and a negative trailing twelve-month return on equity of 72.42%. During the same period last year, the company posted ($0.22) earnings per share.
View Otonomy's earnings history.

What price target have analysts set for OTIC?

2 brokers have issued 12 month price objectives for Otonomy's stock. Their forecasts range from $5.50 to $6.00. On average, they anticipate Otonomy's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 153.3% from the stock's current price.
View analysts' price targets for Otonomy or view top-rated stocks among Wall Street analysts.

Who are Otonomy's key executives?

Otonomy's management team includes the following people:

• David A. Weber, President, Chief Executive Officer & Director
• Paul E. Cayer, Chief Financial & Business Officer
• Fabrice Piu, Vice President-Research & Preclinical Development
• Robert Michael Savel, Chief Technical Officer
• Alan C. Foster, Vice President-Research

Who are some of Otonomy's key competitors?

Some companies that are related to Otonomy include Veru (VERU), PyroGenesis Canada (PYR), Pharming Group (PHAR), Intercept Pharmaceuticals (ICPT), Nkarta (NKTX), Ocular Therapeutix (OCUL), Summit Therapeutics (SMMT), Basilea Pharmaceutica (BPMUF), Rhythm Pharmaceuticals (RYTM), G1 Therapeutics (GTHX), Pliant Therapeutics (PLRX), Pharvaris (PHVS), Deciphera Pharmaceuticals (DCPH), Avadel Pharmaceuticals (AVDL) and BELLUS Health (BLU).
View all of OTIC's competitors.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Who are Otonomy's major shareholders?

Otonomy's stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (2.88%), BlackRock Inc. (1.41%), Dimensional Fund Advisors LP (1.34%), Point72 Asset Management L.P. (1.14%), Renaissance Technologies LLC (1.07%) and Geode Capital Management LLC (0.80%).
View institutional ownership trends for Otonomy.

Which institutional investors are selling Otonomy stock?

OTIC stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Two Sigma Advisers LP, Two Sigma Investments LP, Renaissance Technologies LLC, Squarepoint Ops LLC, and BlackRock Inc..
View insider buying and selling activity for Otonomy or view top insider-selling stocks.

Which institutional investors are buying Otonomy stock?

OTIC stock was purchased by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Point72 Asset Management L.P., Two Sigma Securities LLC, Geode Capital Management LLC, and Barclays PLC.
View insider buying and selling activity for Otonomy or or view top insider-buying stocks.

How do I buy shares of Otonomy?

Shares of OTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $2.27.

How much money does Otonomy make?

Otonomy has a market capitalization of $128.67 million and generates $270 thousand in revenue each year. The biopharmaceutical company earns $-44.73 million in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Otonomy have?

Otonomy employs 56 workers across the globe.

What is Otonomy's official website?

The official website for Otonomy is www.otonomy.com.

Where are Otonomy's headquarters?

Otonomy is headquartered at 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at [email protected], or via fax at 619-291-9190.